Low-dose Morphine Improves Health in COPD Patients With …
WEBSep 3, 2020 · by Steve Bryson, PhD September 3, 2020. Regular, low-dose oral morphine led to significant health improvements in adults with advanced chronic obstructive pulmonary disease (COPD) who regularly experienced shortness of breath, according to results of a Phase 4 clinical trial. Treatment with morphine did …
1st approved Symbicort generic, Breyna, now available in US
WEBAug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 …
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
WEBby Joana Carvalho, PhD June 30, 2020. Breztri Aerosphere, AstraZeneca ’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of …
Wellinks' First Wireless Nebulizer for COPD Cleared for Patient Study
WEBJan 21, 2021 · A pilot study on the first wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) has been cleared by a review board of the U.S. Food and Drug Administration (FDA), Wellinks, the nebulizer’s developer, announced. “Getting into the field with our first digital health offering and welcoming patients on the ...
FDA clears 1st OTC pulse oximeter for home use as medical device
WEBFeb 19, 2024 · The U.S. Food and Drug Administration (FDA) for the first time has cleared a fingertip pulse oximeter for home use as a medical device that consumers — including people with chronic obstructive pulmonary disease (COPD) — can use to check their blood oxygen levels. The device, MightySat Medical from Masimo, is …
Trelegy Ellipta Reduces COPD Exacerbations and Improves Lung …
WEBApr 24, 2018 · Results revealed that treatment with the triple therapy Trelegy Ellipta significantly reduced the number of COPD hospitalizations due to severe exacerbations by 34% compared to Anoro Ellipta. Compared to Breo Ellipta, the reduction was of 13%, but this difference was not statistically significant. The …
People with Stable COPD Seen to Do Better on LAMA Than LABA...
WEBAug 22, 2017 · by Joana Fernandes, PhD August 22, 2017. LAMA (long-acting muscarinic antagonist) treatments may be more beneficial to people with stable chronic obstructive pulmonary disease (COPD) than those with LABA (long-acting beta2-agonist), especially in patients at risk of frequent exacerbations, according to results of a recent review study.
Two Phase 3 Trials of Ensifentrine in Safely Treating COPD to Open
WEBSep 29, 2020 · Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — called ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) — are each expected to enroll up to 800 patients with moderate-to-severe COPD ...
Ultimate Pulmonary Wellness Podcast - COPD News Today
WEBUltimate Pulmonary Wellness Podcast. In this podcast series, pulmonary specialist Dr. Noah Greenspan discusses a variety of issues related to pulmonary diseases, including COPD. Listen to the first four in the series below and follow COPD News Today on SoundCloud for more.
For COPD, Anoro Ellipta Bests Stiolto Respimat in Lung Function …
WEBNov 7, 2017 · The study (NCT02799784) was an open-label, cross-over trial for eight weeks that enrolled 236 COPD patients.Reported results showed that Anoro Ellipta’s effectiveness in improving lung function — measured using the Forced Expiratory Volume in 1 second (FEV1) test at week eight — was not inferior to that of Stiolto Respimat.
Skip to content